Clinical and Instrumental Assessment of the Intestinal State in Children with Respiratory Pathology and Correction of the Revealed Violations
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The need for frequent and long-term use of antibiotic therapy for respiratory pathology of bacterial origin often leads to the development of the intestinal microflora disorders and requires the inclusion of probiotics in treatment regimens. Probiotics containing Bacillus clausii have proven themselves in the treatment of antibiotic associated diarrhea.
The objective: to assess the state of the intestine according to clinical data and the results of hydrogen breath test with lactulose in children with acute respiratory diseases and the effectiveness of the revealed violations correction by adding probiotic containing B. Clausii to the complex therapy.
Materials and methods. Under the supervision there were 38 children of 4–10 years old, who in the course of antibiotic therapy of acute respiratory diseases were added probiotic containing B. Clausii (Probiz kids). In the І group of the study (20 children), probiotic was used simultaneously with antibiotic therapy for 7–10 days course. The ІІ group was formed by 18 children, for 7–10 days they received Probiz kids after completing a course of antibiotics. At the beginning of treatment, at 10–12 and for 25–30 days from the start of therapy, the presence of intestinal manifestations was evaluated and a hydrogen respiratory test with a load of lactulose was performed (HRTLL).
Results. In the first group, on the 10–12th day from the beginning of the study, the syndrome of excessive bacterial growth disappeared in half of the children. But among the children of group II, the normalization of indicators in a repeated study of HRTLL did not occur in one child. On the 25–30 day from the start of treatment, the absence of excessive bacterial growth was detected in 80% of children of the first group and 50% of children of the second group.
Conclusion. The results of the study indicate that probiotic Probiz kids has a positive effect on the intestinal state in children against the background of antibacterial therapy.##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Марушко ЮВ, Асонов АО. Клінічні можливості застосування комплексного пробіотика «Пробіз» з метою профілактики та лікування антибіотико-асоційованої діареї та інших запальних уражень кишечника (огляд літератури) // Современная педиатрия. 2016.8(80):123–128. https://doi.org/10.15574/SP.2016.80.123
McFarland L.V. Antibiotic associated diarrhea: epidemiology, trends and treatment. Future Microbiol. 2008;3(5):563–78. https://doi.org/10.2217/17460913.3.5.563
Hayes SR, Vargas AJ. Probiotics for the Prevention of Pediatric Antibiotic-Associated Diarrhea. Explore (NY). 2016;12(6):463–6. https://doi.org/10.1016/j.explore.2016.08.015
Майданник ВГ. Антибиотик-ассоциированная диарея у детей / В.Г. Майданник. – К., 2011. – 250 c.
Іванько ОГ. Клінічні аспекти антибіотикоасоційованої діареї у дітей // Современная педиатрия. 2014;2(58):101–106. https://doi.org/10.15574/SP.2014.58.101
Марушко ЮВ, Горянська МГ. Оцінка дихального тесту з навантаженням лактулозою в дітей з патологією верхніх відділів травного каналу та корекція виявлених порушень Лактіалє // Здоровье ребенка. 2015;5:34–8. Full text
Закордонец ЛВ, Крамарев СА, Береговая ТВ, Толстанова АН. Антибиотик- ассоциированая диарея: механизмы развития и возможности коррекции // Здоровье ребенка. 2013;7(50):69–73. Full text
Захарова ИН, Бережная ИВ, Дмитриева ЮА, Сугян НГ. Антибиотик-ассоциированные диареи у детей: что нового? РМЖ. 2015;3:128. Full text
Papatheodorou P, Song S, López-Ureña D et al. Cytotoxicity of Clostridium difficile toxins A and B requires an active and functional SREBP-2 pathway. FASEB J. 2019 Apr;33(4):4883–4892. https://doi.org/10.1096/fj.201801440R
Ледоховскі М, Ледоховскі Е, Азенман А. Водородные дыхательные тесты // Інсбрук. «Академія». 2008. 59 с.
Gasbarrini A, Corazza GR, Gasbarrini G, Montalto M. Methodology and indications of H2-breath testing in gastrointestinal diseases: the Rome Consensus Conference // Aliment. Pharmacol. Ther. 2009;30(1):1–49. https://doi.org/10.1111/j.1365-2036.2009.03951.x
Gaffar SMA, Sarker SA, Mahfuz M, Donowitz JR, Ahmed T. Impact of Small Intestine Bacterial Overgrowth on Response to a Nutritional Intervention in Bangladeshi Children from an Urban Community. Am J Trop Med Hyg. 2019;100(1):222–225. https://doi.org/10.4269/ajtmh.18-0759
Petzold G, Amanzada A, Gress TM, Ellenrieder V, Neesse A, Kunsch S. High Prevalence of Pathological Hydrogen Breath Tests in Patients with Functional Dyspepsia.Digestion. 2018;14:1–6. https://doi.org/10.1159/000494718
Banik GD, De A, Som S, Jana S, Daschakraborty SB, Chaudhuri S, Pradhan M. Hydrogen sulphide in exhaled breath: a potential biomarker for small intestinal bacterial overgrowth in IBS. J Breath Res. 2016;10;10(2):026010. https://doi.org/10.1088/1752-7155/10/2/026010
Bures J, Cyrany J, Kohoutova D, et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010;28;16(24):2978–90. https://dx.doi.org/10.3748%2Fwjg.v16.i24.2978
Yao CK, Tuck CJ. The clinical value of breath hydrogen testing. J Gastroenterol Hepatol. 2017;32(l):20–22. https://doi.org/10.1111/jgh.13689
Wang L, Yu YM, Zhang YQ, Zhang J, Lu N, Liu N. Hydrogen breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in autism. Eur Child Adolesc Psychiatry. 2018;27(2):233–240. https://doi.org/10.1007/s00787-017-1039-2
Mantegazza C, Molinari P, D’Auriа E, Sonnino M, Morelli L, Zuccotti GV. Probiotics and antibiotic-associated diarrhea in children: A review and new evidence on Lactobacillus rhamnosus GG during and after antibiotic treatment. Pharmacol Res. 2018;128:63–72. https://doi.org/10.1016/j.phrs.2017.08.001
Sniffen JC, McFarland LV, Evans CT, Goldstein EJC. Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. PloS One. 2018; 26;13(12):e0209205. https://doi.org/10.1371/journal.pone.0209205
Schultz M, Baranchi A, Thurston L, Yu YC, Wang L, Chen J, et al. Consumer demographics and expectations of probiotic therapy in New Zealand: results of a large telephone survey. N Z Med J. 2011;124:36–43.
Clarke TC, Black LI, Stussman BJ, Barnes PM, Nahin RL. Trends in the use of complementary health approaches among adults: United States, 2002–2012. National health statistics reports; no 79. Hyattsville, MD: National Center for Health Statistics. 2015. Available at: https://nccih.nih.gov/research/statistics/NHIS/2012/natural-products/biotics Accessed June 1, 2017.
Draper K, Ley C, Parsonnet J. A survey of probiotic use practices among patients at a tertiary medical centre. Benef Microbes. 2017;8(3):345–351. https://doi.org/10.3920/BM2016.0148
Yi SH, Jernigan JA, McDonald LC. Prevalence of probiotic use among inpatients: A descriptive study of 145 U.S. hospitals. Am J Infect Control 2016;44(5):548–53. https://doi.org/10.1016/j.ajic.2015.12.001
Ianiro G, Rizzatti G, Plomer M et al. Bacillus clausii for the Treatment of Acute Diarrhea in Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients. 2018;12;10(8). pii: E1074. https://doi.org/10.3390/nu10081074
Sudha M.R., Bhonagiri S., Kumar M.A. Efficacy of Bacillus clausii strain UBBC-07 in the treatment of patients suffering from acute diarrhoea. Benef. Microbes. 2013;4:211–216. doi: 10.3920/BM2012.0034. https://doi.org/10.3920/BM2012.0034
McFarland LV, Evans CT, Goldstein EJC. Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis.Front Med (Lausanne). 2018;7;5:124. https://doi.org/10.3389/fmed.2018.00124
